The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.

SAYANA PRESS medroxyprogesterone acetate 104 mg/0.65 mL suspension for injection ampoule with attached needle (401897)

ARTG ID 401897

ARTG Name

SAYANA PRESS medroxyprogesterone acetate 104 mg/0.65 mL suspension for injection ampoule with attached needle

Product name

SAYANA PRESS medroxyprogesterone acetate 104 mg/0.65 mL suspension for injection ampoule with attached needle

ARTG Date

9 August 2023

Registration Type

Medicine

Therapeutic good type

Medicine

Ingredients

medroxyprogesterone acetate

Licence category

RE

Licence status

A

Summary

SAYANA PRESS medroxyprogesterone acetate 104 mg/0.65 mL suspension for injection ampoule with attached needle (2023-24)

2023-24

Annual charge exemption

Exempt from annual charge in 2023-24 due to Pfizer Australia Pty Ltd declaring $0 turnover in that period.
SAYANA PRESS medroxyprogesterone acetate 104 mg/0.65 mL suspension for injection ampoule with attached needle, Pfizer Australia Pty Ltd, CON-1151

4 August 2023

Section 14 consent

Consent to while noncompliant with standards. The consent is effective from 4 August 2023 until 4 August 2025.